Chronic Lymphocytic Leukemia

John Byrd, MD, director of the Division of Hematology, Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, discusses the RESONATE 2 study, which looked at ibrutinib versus chlorambucil in patients with treatment-naïve chronic lymphocytic leukemia (CLL).

Targeted agents, particularly ibrutinib and idelalisib, are becoming increasingly important in the treatment of chronic lymphocytic leukemia, and have replaced chemotherapy in many settings.

Susan O’Brien, MD, Associate Director for Clinical Science for the Chao Family Comprehensive Cancer Center and Medical Director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research, UC Irvine Health, discusses upcoming agents in chronic lymphocytic leukemia (CLL).

Extended follow-up data continue to demonstrate the efficacy and tolerability of ibrutinib in previously treated patients with chronic lymphocytic leukemia, including those with high-risk gene mutations and prognostic features.

Jennifer Brown MD, PhD, Director, Chronic Lymphocytic Leukemia Center, Senior Physician, Associate Professor of Medicine, Harvard Medical School, Dana Farber Cancer Institute, discusses RESONATE 2 and frontline ibrutinib use in patients with chronic lymphocytic leukemia (CLL).

A multitude of PI3K and BTK inhibitors are currently in development that offer distinct advantages over existing treatments for patients with relapsed chronic lymphocytic leukemia.

Frontline treatment with ibrutinib reduced the risk of progression or death by 84% compared with single-agent chlorambucil for elderly patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Mitchell Smith, MD, discusses advancements in the field of non-Hodgkin lymphoma.

A supplemental new drug application has been submitted to the FDA for ofatumumab in combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed chronic lymphocytic leukemia.

The FDA has approved ibrutinib (Imbruvica) for the frontline treatment of chronic lymphocytic leukemia based on data from the RESONATE-2 trial.

Thomas Kipps, MD, PhD, provides insight on the potential impact of an FDA approval for venetoclax, the management of tumor lysis syndrome associated with venetoclax, and combination possibilities for the agent.

Victor Y. Yazbeck, MD, discusses the potential for venetoclax and idelalisib, both as single agents and in combination with other agents, and what questions remain regarding both therapies in CLL.

Jeffrey Jones, MD, discusses exciting data with venetoclax, the role it is likely to have in the treatment paradigm of CLL, and what role it may have alongside ibrutinib and idelalisib.

Farrukh Awan, MBBS, assistant professor of internal medicine, Ohio State University, discusses the role for spleen tyrosine kinase (Syk) inhibitor for the treatment of chronic lymphocytic leukemia (CLL).

The anti-CD19 agent blinatumomab (Blincyto) induced a response rate of 69% in patients with non-Hodgkin Lymphoma.

Entospletinib (GS-9973) has shown early promise as a treatment for pretreated patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Treatment with allogeneic anti–CD19 chimeric antigen receptor–modified T cell therapy induced complete remissions in 30% of patients with advanced progressive B-cell malignancies without causing graft-versus-host disease.

Victor Y. Yazbeck, MD, assistant professor, Hematology-Oncology, Internal Medicine, Virginia Commonwealth University (VCU) School of Medicine, VCU Massey Cancer Center, discusses a phase III study examining idelalisib plus bendamustine rituximab in patients with relapsed/refractory chronic lymphocytic leukemia.

Venetoclax has received an FDA breakthrough therapy designation for use in combination with rituximab to treat patients with relapsed/refractory chronic lymphocytic leukemia.

The FDA has approved ofatumumab (Arzerra) for the extended treatment of patients with recurrent or progressive chronic lymphocytic leukemia who are in complete or partial response following at least two lines of therapy.